Anemia

Patients with chronic kidney disease and TSAT levels of 30–40% experienced significantly fewer cardiovascular events than those with TSAT of 20–30%.

Our May 2024 month-in-review for hematology focuses on the latest updates to the hematologic pipeline.

Nearly half of patients with CKD presented with iron deficiency at the initial presentation at the nephrology department.

Mezagitamab demonstrated no new safety signals and rapid increases in platelet counts across Phase 2b data in treating persistent or chronic ITP.

Exposure to carbon monoxide correlated with lower odds of anemia prevalence, whereas exposure to fine particulate matter had the opposite effect.

Genetically predicted anemia may be casually linked to an increased risk of asthma, suggesting its role in the chronic lung disease's development.

Late-breaking data from EHA 2024 demonstrated a high overall response rate and favorable safety across a range of sHLH patients treated with ELA026.

Bitopertin achieves significant reductions in PPIX versus placebo in patients with erythropoietic protoporphyria.

In the ENERGIZE trial, oral mitapivat achieved meaningful improvements in symptoms of anemia in patients with non-transfusion-dependent thalassemia.

Phase 1/2 EdiTHAL trial data shows reni-cell remained well-tolerated and displayed promising efficacy for patients with TDT.

A higher serum ferritin threshold could lead to better diagnosis and treatment of more women with iron deficiency.

Knowledge, attitudes, and practices remain relevant for disease management among patients with anemia.

Daprodustat 25-30 mg was linked to the most significant rise in serum hemoglobin and reduced serum ferritin levels.

Our May 2024 month-in-review for hematology focuses on important FDA updates, new anemia data from ERA 2024, and the latest imaging modalities.

Diagnostic tests for anemia etiology are infrequently ordered, leading to a significant majority of patients with CKD receiving inadequate treatment.

Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.

An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

Study finds roxadustat effectively treats anemia in both dialysis-dependent and non-dialysis-dependent CKD patients.

The smartphone app demonstrated higher accuracy, sensitivity, and specificity in patients with severe anemia than those with moderate anemia.

Retrospective data suggest the off-label use of IVIg could be helpful in the management of severe autoimmune hemolytic anemia.

Liposomal iron achieves a partial correction of transferrin saturation, with no significant effect on iron storage and hemoglobin, in patients with NDD-CKD.

Automated anemia detection from fundus images may benefit patients undergoing routine retinal imaging.

Announced on May 15, 2024, the IND application supports a phase 1/2 study of CID among adults with chronic ITP.

Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.

An interim analysis of a phase 3 trial displays the effectiveness of prophylaxis with recombinant ADAMTS13, achieving approximately 100% of normal ADAMTS13 levels.

Anemia and iron deficiency are prevalent in heart failure with mildly reduced ejection fraction and may worsen mortality and rehospitalization outcomes.

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

When the current recommended diagnostic algorithm was used in clinical practice, antibody testing was required in half of patients with suspected HIT.

Oral iron supplements did not significantly differ in increasing hemoglobin and ferritin levels, but the every-other-day oral iron proved more effective than daily use.